Scott Coleman
Corporate Officer/Principal chez XILIO THERAPEUTICS, INC.
Profil
Scott Coleman is currently the Chief Development Officer at Xilio Therapeutics, Inc. He previously worked as the Vice President-Non-Clinical Development at Acceleron Pharma, Inc. Dr. Coleman holds a doctorate degree from North Carolina State University and an undergraduate degree from Northeastern University.
Postes actifs de Scott Coleman
| Sociétés | Poste | Début |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2022 |
Anciens postes connus de Scott Coleman
| Sociétés | Poste | Fin |
|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Formation de Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
